___

• 1. Howlett HCS, Bailey CJ. Galegine and antidiabetic plants. In: Bailey CJ, Campbell IW, Chan JCN, Davidson JA, Howlett HCS, Ritz P (eds) Metformin—the gold standard. Wiley, Chichester; 2007, pp 3–9.
• 2. Muller H, Reinwein H. Zur pharmakologie des Galegins. Arch Exp Pathol Pharmakol 1927; 125: 212–228.
• 3. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond.) 2012; 122, 253–270.
• 4. Pryor, R.; Cabreiro, F. Repurposing metformin: An old drug with new tricks in its binding pockets. Biochem. J. 2015; 471, 307–322.
• 5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycae¬mia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6): 1577–1596.
• 6. Polskie Towarzystwo Diabetologiczne. Zalecenia kliniczne dotyczące postępowania z chorym na cukrzycę 2016. Diabetol Klin. 2016; 2(supl. A).
• 7. Segal ED, Yasmeen A, Beauchamp MC, et al. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem. Biophys. Res. Commun. 2011; 414, 694–699.
• 8. Sogame Y, Kitamura A, Yabuki M, et al. Transport of biguanides by human organic cation transporter OCT2. Biomed. Pharmacother. 2013; 67, 425–430.
• 9. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000. 348, 607–614.
• 10. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998, 1659–1663.
• 11. Jin HE, Hong SS, Choi MK, et al. Reduced antidiabetic effect of metformin and downregulation of hepatic Oct1 in rats with ethynylestradiolinduced cholestasis. Pharm. Res. 2009; 26, 549–559.
• 12. Wilcock C, and Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24, 49–57.
• 13. Zhou G, Myers R, Li Y, et al. Role of AMPactivated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108, 1167–1174.
• 14. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310, 1642–1646.
• 15. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 137, 635–646.
• 16. El-Mir MY, Nogueira V, Fontaine E, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000; 275, 223–228.
• 17. Stephenne X, Foretz M, Taleux N, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011; 54, 3101–3110.
• 18. Detaille D, Guigas B, Chauvin C, et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54, 2179–2187.
• 19. El-Mir MY, Detaille D, R-Villanueva et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J. Mol. Neurosci 2008. 34, 77–87.
• 20. Bridges HR, Jones AJ, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 2014; 462, 475–487.
• 21. Wheaton WW, Weinberg SE, Hamanaka RB, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 2014; 3, e02242.
• 22. Correia S, Carvalho C, Santos MS, et al. Mechanisms of action of metformin in type 2 diabetes and associated complications: An overview. Mini Rev. Med. Chem. 2008; 8, 1343–1354.
• 23. Samuel SM, Varghese E, Varghese S, Busselberg D. Challenges and perspectives in the treatment of diabetes associated breast cancer. Cancer Treat. Rev. 2018, 70, 98–111.
• 24. Nesti L, Natali A. Metformine ects on the heart and the cardiovascular system: A review of experimental and clinical data. Nutr. Metab. Cardiovasc. Dis. 2017; 27, 657–669.
• 25. Iranshahy M, Rezaee R, Karimi G. Hepatoprotective activity of metformin: A new mission for an old drug? Eur. J. Pharmacol. 2019;850,1–7.
• 26. Li Y, Liu L, Wang B, et al. Metformin in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Biomed. Rep. 2013; 1, 57–64.
• 27. Yanardag R, Ozsoy-Sacan O, Bolkent S, et al. Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats. Hum. Exp. Toxicol. 2005;24,129–135.
• 28. Brackett CC. Clarifying metformin’s role and risks in liver dysfunction. J. Am. Pharm. Assoc. 2010;50,407–410.
• 29. Corremans R, Vervaet BA, D’Haese PC, et al. Metformin: A Candidate Drug for Renal Diseases. Int. J. Mol. Sci. 2018; 20, 42.
• 30. Rotermund C, Machetanz G, Fitzgerald JC. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Front. Endocrinol. 2018; 9, 400.
• 31. Ma J, Liu J, Yu H, et al. Beneficial Effect of Metformin on Nerve Regeneration and Functional Recovery After Sciatic Nerve Crush Injury in Diabetic Rats. Neurochem. Res. 2016; 41, 1130–1137.
• 32. Mao-Ying QL, Kavelaars A, Krukowski K, et al. The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model. PLoS ONE 2014; 9, e100701.
• 33. Bahrambeigi S, Yousefi B, Rahimi M, Shafiei- Irannejad, V. Metformin; an old antidiabetic drug with new potentials in bone disorders. Biomed. Pharmacother. 2019; 109, 1593–1601.
• 34. Prattichizzo F, Giuliani A, Mensà E, et al. Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. Ageing Res. Rev. 2018, 48, 87–98.
• 35. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a Tool to Target Aging. Cell Metab. 2016;23,1060–1065.
• 36. Novelle MG, Ali A, Dieguez C, et al. Metformin: A Hopeful Promise in Aging Research. Cold Spring Harb. Perspect. Med. 2016; 6, a025932.
• 37. DeCensi A, Puntoni M, Goodwin P, et al. Metformin and Cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010;3:1451–61.
• 38. Zhang ZJ, Zheng ZJ, Kan H, et al, Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis, Diabetes Care 2011;34,2323–2328.
• 39. Zhang ZJ, Zheng ZJ, Shi R, et al. Kip, Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis, J. Clin. Endocrinol. Metab. 2012; 97, 2347–2353.
• 40. Zhang ZJ, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and metaanalysis, Am. J. Epidemiol. 2014;180, 11–14.
• 41. Zhang ZJ, Li S, The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and metaanalysis, Diabetes Obes. Metab. 2014;16,707– 710.
• 42. Boyle P, Boniol M, Koechlin A, et al. Diabetes and breast cancer risk: Ameta-analysis. Br. J. Cancer 2012; 107, 1608–1617.
• 43. Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer: A meta-analysis. Endocr. Relat. Cancer 2012;19,793–803.
• 44. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A metaanalysis. Int. J. Cancer 2007;121,856–862.
• 45. StattinP, Björ O, Ferrari P, et al. Prospective Study of Hyperglycemia and Cancer Risk. Diabetes Care 2007; 30, 561.
• 46. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: A consensus report. Diabetes Care 2010;33,1674–1685.
• 47. Farmer RE, Ford D, Forbes HJ, et al., Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation, Int. J. Epidemiol. 2017;46,728–744.
• 48. Brem RF . Radiofrequency Ablation of Breast Cancer: A Step Forward . Radiological Society of North America; 2018 .
• 49. Warburg O . On the origin of cancer cells. Science .1956;123:309–314.
• 50. Phan LM , Yeung S-CJ , Lee M-H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med . 2014;11:1.
• 51. Camacho L, Dasgupta A, Jiralerspong S. Metformin in breast cancer-an evolving mystery . BioMed Central; 2015.
• 52. Dowling RJ, Niraula S, Chang MC, et al. Changes ininsulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res 2015;17:32.
• 53. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase–dependent growth in- hibitor for breast cancer cells. Cancer Res 2006;66:10269–10273.
• 54. Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions, Endocr. Rev. 2009;30,51–74.
• 55. Husing A, Fortner RT, Kuhn T, et al, Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: results from the EPIC cohort, Clin. Cancer Res. 2017;23,4181– 4189.
• 56. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010;9:1057–1064.
• 57. Gershell L. Type 2 Diabetes Market. Nature Publishing Group; 2005.
• 58. Werner EA, Bell J. CCXIV. The preparation of methylguanidine, and of ββ-dimethylguanidine by the interac- tion of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans. 1922;121:1790–1794.
• 59. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discovery 2013;12:829.
• 60. Evans JMM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–5.
• 61. Saini N, Yang X. Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. Acta Biochim Biophys Sin Shanghai. 2018;50:133–43.
• 62. Tang GH, Satkunam M, Pond GR, et al. Association of metformin with breast cancer incidence and mortality in patients with type 2 diabetes: a GRADE assessed systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2018;27:627–35.
• 63. Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn. 2010;10:509–19.
• 64. Pulito C, Donzelli S, Muti P, et al. microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann Transl Med. 2014;2:58.
• 65. ChenW, Wang S, Tian T, et al. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet. 2009;17:1668–75.
• 66. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015;11:9–15.
• 67. El-Haggar SM, El-Shitany NA, Mostafa MF, El-Bassiouny NA. Metformin may protect nondiabetic breast cancer women from metastasis. Clin Exp Metastasis. 2016;33:339– 57.
• 68. Liu B, Fan Z, Edgerton SM, et al. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 2011;10:2959–66.
• 69. Hatoum D, McGowan EM. Recent advances in the use of metformin: can treating diabetes prevent breast cancer? Biomed Res Int 2015;2015:1–13.
• 70. Pizzuti L, Vici P, Di Lauro L, et al. Metformin and breast cancer: basic knowledge in clinical context. Cancer Treat Rev Elsevier Ltd. 2015;41:441–7.
• 71. Li P, Zhao M, Parris AB, Feng X, Yang X. P53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochem Biophys Res Commun Elsevier Ltd. 2015;464:1267–74.
• 72. Queiroz EAIF, Puukila S, Eichler R, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 2014;9.
• 73. Hu T, Chung YM, Guan M, et al. Reprogramming ovarian and breast cancer cells into noncancerous cells by low-dose metformin or SN-38 through FOXO3 activation. Sci Rep. 2014;4:1–13.
• 74. Davila D, Connolly NMC, Bonner H, et al. Two-step activation of FOXO3 by AMPK generates a coherent feed-forward loop determining excitotoxic cell fate. Cell Death Differ. 2012;19:1677–88.
• 75. Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, et al. Metformin-induced killing of triplenegative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA- 193b. Horm Cancer NIH Public Access 2014;5:374–89.
• 76. Yang J, Wei J, Wu Y, et al. Metformin induces ER stress-dependent apoptosis through miR- 708-5p/ NNAT pathway in prostate cancer. Oncogenesis 2015;4:e158–8.
• 77. Li W, Yuan Y, Huang L, Qiao M, Zhang Y. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 2012;96:187–95.
• 78. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et al. Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle 2012;11:1235–46.
• 79. Zhang J, Li G, Chen Y, et al. Metformin inhibits tumorigenesis and tumor growth of breast cancer cells by upregulating miR-200c but downregulating AKT2 expression. J Cancer 2017;8:1849–64.
• 80. Zhao W, Zhang X, Liu J, et al. miR-27amediated antiproliferative effects of metformin on the breast cancer cell line MCF-7. Oncol Rep 2016;36:3691–9.